Valuation: Affimed N.V.

Market Cap 1.88Cr 2.15Cr 1.74Cr 1.6Cr 3.04Cr 205.14Cr 3.09Cr 21Cr 8.14Cr 101.04Cr 8.07Cr 7.9Cr 347.73Cr P/E 2022
-1.92x
P/E 2023 -0.8x
Enterprise Value -3L -4L -3L -3L -5L -3.66Cr -6L -37.08L -14.53L -1.8Cr -14.41L -14.09L -6.21Cr EV / Sales 2022
0.03x
EV / Sales 2023 4.69x
Free-Float
92.89%
Yield 2022 *
-
Yield 2023 -
1 week 0
Extreme 0
0
1 month 0
Extreme 0
0
Current year 0
Extreme 0
0.04
1 year 0
Extreme 0
0.07
3 years 0
Extreme 0
8.95
5 years 0
Extreme 0
73.5
10 years 0
Extreme 0
117.4
Manager TitleAgeSince
Chief Executive Officer 42 03/09/2024
Director of Finance/CFO 61 31/12/2023
Chief Executive Officer 65 15/01/2024
Director TitleAgeSince
Chairman 75 01/01/2007
Director/Board Member 71 21/01/2016
Director/Board Member 60 04/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-99.77%-100.00% 1.64T
-4.14%-8.06%+57.35%+117.24% 5.7TCr
+1.84%+1.65%+76.90%+95.68% 5.36TCr
-2.24%+3.59%+19.60%+466.72% 2.56TCr
-1.60%-6.21%-19.69%-14.84% 2.35TCr
+2.43%+1.06%+47.70%-0.11% 1.94TCr
-3.19%0.00%+33.99%-26.87% 1.81TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
+8.74%+3.51%+53.81% - 1.41TCr
-1.05%+1.16%+25.08%+196.28% 1.44TCr
Average -0.60%+1.05%+39.01%+121.25% 2.42TCr
Weighted average by Cap. -1.02%+0.29%+54.92%+138.67%

Financials

2022 2023
Net sales 4.29Cr 4.89Cr 3.95Cr 3.65Cr 6.92Cr 466.75Cr 7.04Cr 47Cr 19Cr 229.88Cr 18Cr 18Cr 791.16Cr 1.39Cr 1.59Cr 1.28Cr 1.19Cr 2.25Cr 151.49Cr 2.28Cr 15Cr 6.01Cr 75Cr 5.96Cr 5.83Cr 256.79Cr
Net income -8.6Cr -9.82Cr -7.93Cr -7.32Cr -14Cr -936.39Cr -14Cr -95Cr -37Cr -461.19Cr -37Cr -36Cr -1.59TCr -11Cr -12Cr -9.77Cr -9.02Cr -17Cr -1.15TCr -17Cr -116.8Cr -46Cr -568.09Cr -45Cr -44Cr -1.96TCr
Net Debt -17Cr -20Cr -16Cr -15Cr -28Cr -1.87TCr -28Cr -189.73Cr -74Cr -922.86Cr -74Cr -72Cr -3.18TCr -1.92Cr -2.19Cr -1.77Cr -1.63Cr -3.1Cr -208.81Cr -3.15Cr -21Cr -8.29Cr -102.84Cr -8.22Cr -8.04Cr -353.94Cr
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Employees
76
Date Price Change Volume
09/26/09 $0.000100 0.00% 2,304
07/26/07 $0.000100 +9,900.00% 2,923
06/26/06 $0.000001 -99.00% 1,000

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AFMDQ Stock